PDF(Pubmed)
Abstract：
Clear cell carcinoma is a high-risk subtype of endometrial cancer. Some patients have a mixture of clear cell carcinoma with other histologic types (endometrioid or serous) or cannot be neatly assigned to one of these types. Protocol GOG-8032 within GOG-210 was designed to determine whether these tumors differ from pure clear cell carcinoma in stage at diagnosis, initial pattern of spread, or patient survival.
The term \"mixed\" was applied to tumors with multiple identifiable components, and \"indeterminate\" was applied to tumors with features intermediate between different histologic types. Three hundred eleven women with pure, mixed, or indeterminate clear cell carcinoma were identified in a larger cohort of patients undergoing hysterectomy for endometrial cancer in GOG-210. Histologic slides were centrally reviewed by expert pathologists. Baseline and follow-up data were analyzed.
One hundred thirty-six patients had pure clear cell carcinoma and 175 had a mixed or indeterminate clear cell pattern. Baseline clinicopathologic characteristics were similar except for a small difference in age at presentation. Univariate survival analysis confirmed the significance of typical endometrial cancer prognostic factors. Patients in the mixed categories had disease-free and overall survival similar to pure clear cell carcinoma, but the indeterminate clear cell/endometrioid group had longer survival.
In clear cell endometrial cancer, the presence of a definite admixed endometrioid or serous component did not correlate with a significant difference in prognosis. Patients whose tumors had indeterminate clear cell features had better prognosis. Some of these tumors may be endometrioid tumors mimicking clear cell carcinoma.
The term \"mixed\" was applied to tumors with multiple identifiable components, and \"indeterminate\" was applied to tumors with features intermediate between different histologic types. Three hundred eleven women with pure, mixed, or indeterminate clear cell carcinoma were identified in a larger cohort of patients undergoing hysterectomy for endometrial cancer in GOG-210. Histologic slides were centrally reviewed by expert pathologists. Baseline and follow-up data were analyzed.
One hundred thirty-six patients had pure clear cell carcinoma and 175 had a mixed or indeterminate clear cell pattern. Baseline clinicopathologic characteristics were similar except for a small difference in age at presentation. Univariate survival analysis confirmed the significance of typical endometrial cancer prognostic factors. Patients in the mixed categories had disease-free and overall survival similar to pure clear cell carcinoma, but the indeterminate clear cell/endometrioid group had longer survival.
In clear cell endometrial cancer, the presence of a definite admixed endometrioid or serous component did not correlate with a significant difference in prognosis. Patients whose tumors had indeterminate clear cell features had better prognosis. Some of these tumors may be endometrioid tumors mimicking clear cell carcinoma.
摘要：
目的：透明细胞癌是子宫内膜癌的高危亚型。一些患者患有透明细胞癌与其他组织学类型（子宫内膜样或浆液性）的混合物，或者不能被整齐地分配到这些类型之一。GOG-210中的GOG-8032方案旨在确定这些肿瘤在诊断阶段是否与纯透明细胞癌不同。最初的传播模式，或患者生存。
方法：术语“混合”适用于具有多种可识别成分的肿瘤，和“不确定”应用于特征介于不同组织学类型之间的肿瘤。三百11个女人与纯洁，混合,在GOG-210中,在接受子宫内膜癌切除术的更大队列患者中发现或不确定的透明细胞癌.病理专家对组织学载玻片进行了集中审查。分析基线和随访数据。
结果：136例患者患有纯透明细胞癌，175例患者患有混合或不确定的透明细胞模式。基线临床病理特征相似，只是在就诊时年龄差异很小。单因素生存分析证实了典型子宫内膜癌预后因素的意义。混合类别的患者的无病生存期和总生存期与纯透明细胞癌相似，但不确定的透明细胞/子宫内膜样组的生存期更长。
结论：在透明细胞子宫内膜癌中，明确混合的子宫内膜样或浆液成分的存在与预后无显著差异。肿瘤具有不确定的透明细胞特征的患者预后较好。这些肿瘤中的一些可能是模仿透明细胞癌的子宫内膜样肿瘤。
方法：术语“混合”适用于具有多种可识别成分的肿瘤，和“不确定”应用于特征介于不同组织学类型之间的肿瘤。三百11个女人与纯洁，混合,在GOG-210中,在接受子宫内膜癌切除术的更大队列患者中发现或不确定的透明细胞癌.病理专家对组织学载玻片进行了集中审查。分析基线和随访数据。
结果：136例患者患有纯透明细胞癌，175例患者患有混合或不确定的透明细胞模式。基线临床病理特征相似，只是在就诊时年龄差异很小。单因素生存分析证实了典型子宫内膜癌预后因素的意义。混合类别的患者的无病生存期和总生存期与纯透明细胞癌相似，但不确定的透明细胞/子宫内膜样组的生存期更长。
结论：在透明细胞子宫内膜癌中，明确混合的子宫内膜样或浆液成分的存在与预后无显著差异。肿瘤具有不确定的透明细胞特征的患者预后较好。这些肿瘤中的一些可能是模仿透明细胞癌的子宫内膜样肿瘤。
